Great deck and missing a few more like the molecules they sold to Roivant, Cerevel etc that others were able to bring to mkt. Also missing things like Bold Move 3.3, failed transformation of the commercial model, potential appearance of conflict of interest by being Adobe's guinea pig for new product development when their CEO is also on the board and setting up that IT hub in the CEO's home town in Greece - nothing against Greece but why not Silicon Valley or Cambridge UK and why that particular place in Greece - doesn't look like proper oversight of CEO by BoD.Starboard have posted their whole attack ad, not many solutions. just telling investors that Pfizer isn't good at developing drugs. A lot of people discussing it.
https://www.starboardvalue.com/wp-c...tive-Passive_Investor_Summit_-_Pfizer_Inc.pdf
Even they couldn’t figure out what BM 3.3 was supposed to be or where the dumb name even came from.Great deck and missing a few more like the molecules they sold to Roivant, Cerevel etc that others were able to bring to mkt. Also missing things like Bold Move 3.3, failed transformation of the commercial model, potential appearance of conflict of interest by being Adobe's guinea pig for new product development when their CEO is also on the board and setting up that IT hub in the CEO's home town in Greece - nothing against Greece but why not Silicon Valley or Cambridge UK and why that particular place in Greece - doesn't look like proper oversight of CEO by BoD.
Covid windfall of taxpayer dollars that they used to enrich shareholders, a few top execs and buy Seagen. Nothing more.Thorough and enlightening slides. Pfe spent Covid windfall mostly on ONE company. Terrible asset management. Of course, they’ll probably do some trickle down tactics and blame the reps and market for poor sales.
I think the shareholders that were enriched were also the Execs who, miraculously, had planned options sales at the very top of the covid bonanza. At the same time, they were pumping the stock with covid promises they knew were not likely trueCovid windfall of taxpayer dollars that they used to enrich shareholders, a few top execs and buy Seagen. Nothing more.
Schutta, Jim S, Nick L sold BM 3.3 like it was going to cure cancer and world hunger. “Skating to where the puck is”…”Giving our customers what they are asking for”…call centers…bwahaha. If investors only knew how decisions get made.I blame Shutta’s fat ass for Bowel Movement 3.3.
Those clowns thought that what worked for office managers and CNAs in pediatrician offices would also work in other MD offices. Absolute clown showSchutta, Jim S, Nick L sold BM 3.3 like it was going to cure cancer and world hunger. “Skating to where the puck is”…”Giving our customers what they are asking for”…call centers…bwahaha. If investors only knew how decisions get made.
Would you support breaking up the company?BioSpace headline says analysts rally around PFE leadership. However when I read the article, I don’t really see support stated for AB, leadership or the board. What I read is an acknowledgement that a quick fix is not likely. The question is: if a quick fix is not likely, do you really think the ones who dug this deep hole are the ones to get us out of it? PFE is below the 10 year share price, options are worthless and I have zero confidence that current PFE leadership will produce appreciably improved results within 5 years.
5 years is a lifetime for investors to hope for something better than sideways movement. As an investment, PFE stinks and so do the leadership decisions that got it to this sorry spot.
YesWould you support breaking up the company?
Surprised they didn’t touch on the women’s health external investments.Great deck and missing a few more like the molecules they sold to Roivant, Cerevel etc that others were able to bring to mkt. Also missing things like Bold Move 3.3, failed transformation of the commercial model, potential appearance of conflict of interest by being Adobe's guinea pig for new product development when their CEO is also on the board and setting up that IT hub in the CEO's home town in Greece - nothing against Greece but why not Silicon Valley or Cambridge UK and why that particular place in Greece - doesn't look like proper oversight of CEO by BoD.
